Skip to main content
. Author manuscript; available in PMC: 2019 Oct 29.
Published in final edited form as: JCO Precis Oncol. 2019 Sep 20;3:10.1200/po.19.00119. doi: 10.1200/PO.19.00119

FIG 2.

FIG 2.

Kaplan-Meier curves for overall survival in our patient cohort with survival data. (A) Survival of responders compared with nonresponders. (B) Survival of male compared with female patients. (C) Survival of patients treated with azacitidine compared with patients treated with decitabine. (D) Survival of patients who received hypomethylating agent as a single agent compared with patients who received it in combination with other drugs. (E) Survival of patients on the basis of International Prognostic Scoring System (IPSS)–revised risk categories.